

Physician initiated five year follow-up elevates BX stent graft long-term data





Note: Key differences in study design and patient population hinder a direct comparison of results from COBEST and physician-initiated study.



Demonstrated long-term durable outcomes through five years1

Complex aortoiliac occlusive disease treatment.

89.5%

Primary patency at five years per lesion

96.1%

Primary assisted patency at five years per lesion

89.1%

fTLR at five years per subject

This physician-initiated study enrolled 59 patients from three participating centers that were representative of the VBX FLEX Study three-year follow-up cohort.

28 patients completed five-year follow-up.



References

- 1. Holden A. Takele E. Hill A. et al. Long-term follow-up of subjects with aortoiliac occlusive disease treated with the VIABAHN VBX balloon expandable endoprosthesis. Presented at Cardiovascular & Interventional Radiological Society of Europe (CIRSE) 2022; September 10-14, 2022; Barcelona, Spain. CardioVascular & Interventional Radiology 2022;45:Supplement:S147. Abstract 301.1.
- 2. Mwipatayi BP, Sharma S, Daneshmand A, et al; COBEST co-investigators. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. Journal of Vascular Surgery 2016;64(1):83-94.e1.

Consult Instructions for Use

eifu.goremedical.com

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. $R_{X\,\text{Only}}$

Products listed may not be available in all markets.

GORE, Together, improving life, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2022 W. L. Gore & Associates GmbH 22776394-EN NOVEMBER 2022

